The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

Guven, Deniz Can; kertmen, neyran; Sahin, Taha Koray; Cakir, Ibrahim Yahya; Aktepe, Oktay Halit; Yıldırım, Hasan Çağrı; Dizdar, Omer; AKSOY, SERCAN; Erul, Enes

doi:10.55730/1300-0144.5495

The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

Deniz Can GÜVEN, (Hacettepe Üniversitesi, Kanser Enstitüsü, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Hasan Çağrı YILDIRIM, (Hacettepe Üniversitesi, Kanser Enstitüsü, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Enes ERUL, (Hacettepe Üniversitesi, Tıp Fakültesi, Dahiliye Anabilim Dalı, Ankara, Türkiye)

Taha Koray ŞAHİN, (Hacettepe Üniversitesi, Tıp Fakültesi, Dahiliye Anabilim Dalı, Ankara, Türkiye)

Ibrahim Yahya Cakir, (Hacettepe Üniversitesi, Tıp Fakültesi, Dahiliye Anabilim Dalı, Ankara, Türkiye)

Oktay Halit AKTEPE, (Hacettepe Üniversitesi, Kanser Enstitüsü, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Neyran KERTMEN, (Hacettepe Üniversitesi, Kanser Enstitüsü, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Ömer DİZDAR, (Hacettepe Üniversitesi, Kanser Enstitüsü, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Sercan AKSOY (Hacettepe Üniversitesi, Kanser Enstitüsü, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Turkish Journal of Medical Sciences

6 0

Yıl: 2022 Cilt: 52 Sayı: 5 Sayfa Aralığı: 1551 - 1558 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5495 İndeks Tarihi: 27-12-2022

The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

Öz:

Background/aim: We aimed to evaluate the efficacy of fulvestrant and its affecting clinical factors, including the optimal sequencing of fulvestrant and chemotherapy in a real-life cohort. Methods: The data of 256 metastatic hormone-positive breast cancer patients treated with fulvestrant were evaluated. The association of clinical factors with survival was analyzed with Kaplan-Meier and Cox-regression analyses. Results: The median age of patients was 57 years. More than half of the patients used fulvestrant in later lines and after chemotherapy (75.8%). The median progression-free (PFS) and overall survival (OS) of all cohort were 6.05 ± 0.56 and 29.70 ± 1.61 months, respectively. Primary endocrine resistance (HR: 1.989, 95% CI: 1.430–2.766, <0.001), use of fulvestrant after chemotherapy (HR: 1.849, 95% CI: 1.182–2.891, p = 0.007) and visceral metastases (HR: 1.587, 95% CI: 1.128–2.233, p = 0.008) were associated with decreased OS in multivariate analyses. Sixteen patients were treated with trastuzumab and fulvestrant combination. The overall response rate (p = 0.340), disease control rate (p = 0.076), and OS (p = 0.289) and PFS (p = 0.276) were similar to overall cohort. Conclusion: In our experience, fulvestrant treatment was associated with comparable OS to clinical trials in a large cohort of patients. Patients treated with fulvestrant before chemotherapy were garnered significantly more benefit.

Anahtar Kelime: Fulvestrant hormone-positive breast cancer real-life FALCON study

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394-424. https://doi. org/10.3322/caac.21492
2. Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Frontiers in Oncology 2018; 8 (227). https://doi.org/10.3389/fonc.2018.00227
3. Guo F, Kuo Y-f, Shih YCT, Giordano SH, Berenson AB. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer 2018; 124 (17): 3500-3509. https://doi.org/10.1002/cncr.31638
4. Aggelis V, Johnston SRD. Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs 2019; 79 (17): 1849-1866. https://doi. org/10.1007/s40265-019-01208-8
5. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. British Journal of Cancer 2004; 90 (1): S2-S6. https:// doi.org/10.1038/sj.bjc.6601629
6. Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet 2016; 388 (10063): 2997-3005. https://doi.org/10.1016/ S0140-6736(16)32389-3
7. Palumbo R, Sottotetti F, Quaquarini E, Gambaro A, Ferzi A et al. Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor- positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience. Therapeutic Advances in Medical Oncology 2019; 11: 1758835919833864. https://doi. org/10.1177/1758835919833864
8. Lau E, McCoy P, Reeves F, Chow K, Clarkson M et al. Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. Genome Medicine 2020; 12 (1): 72. https://doi.org/10.1186/s13073-020-00770-1
9. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31 (12): 1623-1649. https://doi.org/10.1016/j.annonc.2020.09.010
10. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28 (30): 4594-4600. https://doi.org/10.1200/ jco.2010.28.8415
11. Telford C, Bertranou E, Large S, Phelps H, Ekman M et al. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. PharmacoEconomics - Open 2019; 3 (4): 559-570. https:// doi.org/10.1007/s41669-019-0134-3
12. Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nature Reviews Clinical Oncology 2019; 16 (5): 312-325. https://doi.org/10.1038/ s41571-019-0167-7
13. Huang J, Huang P, Shao X-y, Sun Y, Lei L et al. Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series. Medicine 2020; 99 (29): e20821. https://doi.org/10.1097/ md.0000000000020821
14. Lei W, Li H, Song G, Zhang R, Ran R et al. Abstract P5-11- 20: Efficacy observation of 306 patients with fulvestrant 500mg treatment in hormone-receptor positive HER2 negative metastasis breast cancer, a real world study. Cancer Research 2020; 80 (4 Supplement): P5-11-20-P15-11-20. https://doi. org/10.1158/1538-7445.Sabcs19-p5-11-20
15. Skinner KE, Olufade T, Walker MS, Schwartzberg LS. Real- world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer. The Breast Journal 2020; 26 (2): 112-119. https://doi. org/10.1111/tbj.13492
16. Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G et al. Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute 2020. https://doi.org/10.1093/jnci/ djaa071
17. Graham J, Pitz M, Gordon V, Grenier D, Amir E et al. Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. Cancer Treatment Reviews 2016; 45: 1-6. https://doi. org/10.1016/j.ctrv.2016.02.004
18. Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D et al. Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. Oncotarget 2017; 8 (40): 69025-69037. https://doi.org/10.18632/oncotarget.16982
19. Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Annals of Oncology 2013; 24 (11): 2715-2724. https://doi.org/10.1093/annonc/ mdt287
20. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11 (13): 4741- 4748. https://doi.org/10.1158/1078-0432.Ccr-04-2569
21. Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J et al. Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer. The Oncologist 2010; 15 (2): 122-129. https:// doi.org/10.1634/theoncologist.2009-0240
22. Johnston S, Pippen J, Jr., Pivot X, Lichinitser M, Sadeghi S et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27 (33): 5538-5546. https://doi.org/10.1200/jco.2009.23.3734
23. Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor- positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012; 21 (1): 27-33. https://doi.org/10.1016/j. breast.2011.07.006
24. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27 (33): 5529-5537. https:// doi.org/10.1200/jco.2008.20.6847
25. Robertson JFR, Steger GG, Neven P, Barni S, Gieseking F et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Annals of Oncology 2010; 21 (6): 1246-1253. https://doi.org/10.1093/annonc/mdp447
26. Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso- Sandoval TA et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 2020; 21 (6): 763-775. https://doi.org/10.1016/s1470-2045(20)30112-1

APA	Guven D, Yıldırım H, Erul E, Sahin T, Cakir I, Aktepe O, kertmen n, Dizdar O, AKSOY S (2022). The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. , 1551 - 1558. 10.55730/1300-0144.5495
Chicago	Guven Deniz Can,Yıldırım Hasan Çağrı,Erul Enes,Sahin Taha Koray,Cakir Ibrahim Yahya,Aktepe Oktay Halit,kertmen neyran,Dizdar Omer,AKSOY SERCAN The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. (2022): 1551 - 1558. 10.55730/1300-0144.5495
MLA	Guven Deniz Can,Yıldırım Hasan Çağrı,Erul Enes,Sahin Taha Koray,Cakir Ibrahim Yahya,Aktepe Oktay Halit,kertmen neyran,Dizdar Omer,AKSOY SERCAN The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. , 2022, ss.1551 - 1558. 10.55730/1300-0144.5495
AMA	Guven D,Yıldırım H,Erul E,Sahin T,Cakir I,Aktepe O,kertmen n,Dizdar O,AKSOY S The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. . 2022; 1551 - 1558. 10.55730/1300-0144.5495
Vancouver	Guven D,Yıldırım H,Erul E,Sahin T,Cakir I,Aktepe O,kertmen n,Dizdar O,AKSOY S The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. . 2022; 1551 - 1558. 10.55730/1300-0144.5495
IEEE	Guven D,Yıldırım H,Erul E,Sahin T,Cakir I,Aktepe O,kertmen n,Dizdar O,AKSOY S "The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study." , ss.1551 - 1558, 2022. 10.55730/1300-0144.5495
ISNAD	Guven, Deniz Can vd. "The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study". (2022), 1551-1558. https://doi.org/10.55730/1300-0144.5495

APA	Guven D, Yıldırım H, Erul E, Sahin T, Cakir I, Aktepe O, kertmen n, Dizdar O, AKSOY S (2022). The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. Turkish Journal of Medical Sciences, 52(5), 1551 - 1558. 10.55730/1300-0144.5495
Chicago	Guven Deniz Can,Yıldırım Hasan Çağrı,Erul Enes,Sahin Taha Koray,Cakir Ibrahim Yahya,Aktepe Oktay Halit,kertmen neyran,Dizdar Omer,AKSOY SERCAN The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. Turkish Journal of Medical Sciences 52, no.5 (2022): 1551 - 1558. 10.55730/1300-0144.5495
MLA	Guven Deniz Can,Yıldırım Hasan Çağrı,Erul Enes,Sahin Taha Koray,Cakir Ibrahim Yahya,Aktepe Oktay Halit,kertmen neyran,Dizdar Omer,AKSOY SERCAN The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. Turkish Journal of Medical Sciences, vol.52, no.5, 2022, ss.1551 - 1558. 10.55730/1300-0144.5495
AMA	Guven D,Yıldırım H,Erul E,Sahin T,Cakir I,Aktepe O,kertmen n,Dizdar O,AKSOY S The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. Turkish Journal of Medical Sciences. 2022; 52(5): 1551 - 1558. 10.55730/1300-0144.5495
Vancouver	Guven D,Yıldırım H,Erul E,Sahin T,Cakir I,Aktepe O,kertmen n,Dizdar O,AKSOY S The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study. Turkish Journal of Medical Sciences. 2022; 52(5): 1551 - 1558. 10.55730/1300-0144.5495
IEEE	Guven D,Yıldırım H,Erul E,Sahin T,Cakir I,Aktepe O,kertmen n,Dizdar O,AKSOY S "The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study." Turkish Journal of Medical Sciences, 52, ss.1551 - 1558, 2022. 10.55730/1300-0144.5495
ISNAD	Guven, Deniz Can vd. "The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study". Turkish Journal of Medical Sciences 52/5 (2022), 1551-1558. https://doi.org/10.55730/1300-0144.5495